Please assess the completion status of the following clinical trial:

Trial Title: The ORTIZ Study: Optimising RASi Therapy With SZC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to provide written informed consent~2. Adults ≥ 18years old~3. Type 2 Diabetes~4. CKD defined as eGFR 25-60ml/min~5. Albuminuria with uACR measured at \>33.9.mg/mmol (300mg/g)~6. On a stable (\>4 weeks) of sub-maximal RASi dose, defined as any ACE or ARB dose up to and including 50% of maximum dose with evidence of hyperkalaemia potassium level \>5.0mmol/l OR not currently on RASi therapy due to documented issues of hyperkalaemia in the past necessitating RASi discontinuation~Exclusion Criteria:~1. Active malignancy~2. Patients who lack capacity to give informed consent~3. GI disturbance/chronic diarrhoea/stoma~4. Subjects with a life expectancy of less than 3 months.~5. Women who are pregnant, lactating, planning to become pregnant or unwilling to use effective methods of contraception during the study.~6. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated including NYHA class III/IV.~7. History of acute eGFR fall with RASi therapy (\>30% in eGFR on initiation of RASi therapy)~8. Known hypersensitivity or previous anaphylaxis to SZC or Irbesartan~9. Hypotension: BP \<120/70mm/hg at screening despite no antihypertensive agent use~10. Uncontrolled Blood pressure: BP \>170/110 at screening~11. Evidence of prolonged QT on ECG QTc(f)\>550msec~12. History of QT prolongation associated with other medications that required discontinuation of that medication~13. Treatment with lithium, or dual blockade with ACEi and ARB or mineralocorticoid inhibitor~14. History of congenital long QT syndrome~15. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted~16. Current or recent (within 3 months) participation in a clinical trial involving an investigational medicinal product.~17. Current treatment with a potassium binder medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SZC (Type: EXPERIMENTAL): 3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
- Placebo (Type: PLACEBO_COMPARATOR): 3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits

Based on this trial design, predict the completion outcome and termination type (if applicable).